dalcetrapib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Dalcetrapib is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of HDL cholesterol. Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.   Wikipedia

Chemistry

  • SMILES: Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21
  • InChIKey: JYYLVUFNAHSSFE-UHFFFAOYSA-N
  • Mol. Mass: 406.39
  • ALogP: 1.94
  • ChEMBL Molecules:
    pamapimod  
    dalcetrapib  
More Chemistry

Pharmacology

Alternative names

dalcetrapib | jtt-705 | ro-4607381 | s-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Acute Coronary Syndrome (Phase 3)

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

COVID-19 (Phase 2)

Dyslipidemias (Phase 3)

Healthy Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue